<?xml version="1.0" encoding="UTF-8"?>
<p>Lo et al. (
 <xref rid="CIT0044" ref-type="bibr">2019</xref>) also displayed that RDV prevent Nipah virus infection in monkeys. Furthermore, to assess the reduction of MERS-CoV infection 
 <italic>in vivo</italic>, Sheahan et al. (
 <xref rid="CIT0064" ref-type="bibr">2020</xref>) demonstrated that RDV stimulate superior antiviral function against MERS-CoV in cell culture and animal models as compared with other conventional anti-viral agents (
 <xref ref-type="fig" rid="F0004">Figure 4</xref>). Furthermore, they found that RDV was the only therapeutic agent which remarkably decreased pulmonary infection.
</p>
